Trial Profile
Observation study of Infliximab (CT-P13) in patients with fistulizing Crohn's disease (FCD) and moderate to severe active Crohn's disease (CD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Feb 2017
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 23 Feb 2017 According to a Celltrion media release, results from this study were presented at the 12th Congress of the European Crohns and Colitis Organisation (ECCO),
- 23 Feb 2017 New trial record